Phoenix Biotech Acquisition Corp (PBAX) Peer Comparison
$5.20
As on 14-Feb-2024 18:35EDT
Market cap
$36 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
123.7
Div. Yield
0 %
| Phoenix Biotech Acquisition Corp (PBAX) | Williams Rowland Acquisition (WRAC) | |
|---|---|---|
Market cap ($ Mln) |
36 | 88 |
Revenue ($ Mln) |
0 | -- |
Net Profit ($ Mln) |
-2.41 | 2.39 |
Net Margin (%) |
-114.42 | 108.05 |
RoE (%) |
-- | 10.81 |
Price to Earnings |
-- | 262.50 |
Price-To-Book |
123.73 | 5.04 |
Income Statement ($ Mln)
| Phoenix Biotech Acquisition Corp (PBAX) | Williams Rowland Acquisition (WRAC) | |
|---|---|---|
|
Operating Revenue
|
0.25 | 0.00 |
|
Cost of Revenue
|
0.00 | 2.19 |
|
Gross Profit
|
0.25 | -1.57 |
|
Operating Expenses
|
3.85 | 0.87 |
|
Operating Profit (EBIT)
|
-1.33 | -0.87 |
|
Other Income
|
1.85 | 2.21 |
|
Profit before Tax
|
-1.91 | 3.41 |
|
Provision for Tax
|
0.50 | 1.02 |
|
Profit after Tax (Net Income)
|
-2.41 | 2.39 |
|
Minority Interest
|
0.00 | 0.00 |
|
Consolidated Profit
|
-2.93 | 2.41 |
Liabilities ($ Mln)
| Phoenix Biotech Acquisition Corp (PBAX) | Williams Rowland Acquisition (WRAC) | |
|---|---|---|
|
Shareholder's Funds
|
-5.48 | 17.37 |
|
Minority Interest
|
0.00 | 0.00 |
|
Non-Current Liabilities
|
9.15 | 8.05 |
|
Current Liabilities
|
4.80 | 2.01 |
|
Total Liabilities
|
42.37 | 36.60 |
Assets ($ Mln)
| Phoenix Biotech Acquisition Corp (PBAX) | Williams Rowland Acquisition (WRAC) | |
|---|---|---|
|
Non-Current Assets
|
0.00 | 27.21 |
|
Current Assets
|
8.47 | 0.23 |
|
Total Assets
|
42.37 | 36.60 |
|
Total Debt*
|
1.40 | 1.33 |
|
Net Current Assets
|
3.67 | -1.79 |
Cashflow ($ Mln)
| Phoenix Biotech Acquisition Corp (PBAX) | Williams Rowland Acquisition (WRAC) | |
|---|---|---|
|
Cash From Operating Activities
|
-1.09 | -1.31 |
|
Cash Flow from Investing Activities
|
180.84 | 201.94 |
|
Cash from Financing Activities
|
-138.70 | -200.75 |
|
Net Cash Inflow / Outflow
|
41.04 | -0.13 |
Ratios
Profitability Ratios
| Phoenix Biotech Acquisition Corp (PBAX) | Williams Rowland Acquisition (WRAC) | |
|---|---|---|
|
ROCE (%)
|
-0.77 | 0.80 |
|
ROE (%)
|
-0.77 | 10.81 |
|
ROA (%)
|
-2.47 | 1.79 |
|
EBIT Margin (%)
|
-521.20 | -- |
|
Net Margin (%)
|
-114.42 | 108.05 |
|
Cash Profit Margin (%)
|
-- | -- |
Growth Ratios
| Phoenix Biotech Acquisition Corp (PBAX) | Williams Rowland Acquisition (WRAC) | |
|---|---|---|
|
Revenue Growth (%)
|
-- | -- |
|
EBIT Growth (%)
|
100.00 | 169.58 |
|
Net Profit Growth (%)
|
-100.00 | 514.17 |
|
EPS Growth (%)
|
-- | 460.22 |
|
Book Value Growth (%)
|
-- | -92.34 |
Valuation Ratios
| Phoenix Biotech Acquisition Corp (PBAX) | Williams Rowland Acquisition (WRAC) | |
|---|---|---|
|
Price / Earnings
|
-- | 58.99 |
|
Price / Book Value
|
-- | 2.24 |
|
Dividend Yield (%)
|
-- | -- |
|
EV/EBITDA
|
-0.03 | -15.58 |
|
Market Cap ($ Cr)
|
-- | -- |
Solvency Ratios
| Phoenix Biotech Acquisition Corp (PBAX) | Williams Rowland Acquisition (WRAC) | |
|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 |
|
Short term debt to equity ratio
|
-0.25 | 0.08 |
|
Current Ratio
|
1.76 | 0.11 |
|
Quick Ratio
|
1.76 | 0.11 |
|
Interest Coverage
|
-8.06 | 2.79 |
Operating Efficiency Ratios
| Phoenix Biotech Acquisition Corp (PBAX) | Williams Rowland Acquisition (WRAC) | |
|---|---|---|
|
Debtors to sales (%)
|
0.00 | -- |
|
Asset Turnover
|
0.00 | 0.00 |
|
Receivable days
|
-- | -- |
|
Inventory Days
|
-- | -- |
|
Payable days
|
-- | 127.50 |
|
Cash Conversion Cycle
|
-- | -- |